Congress:
EuroSafe Imaging 2021
Keywords:
Breast, Contrast agents, Radioprotection / Radiation dose, Mammography, Contrast agent-intravenous, Dosimetry, Radiation safety, Cancer, Multidisciplinary cancer care, Quality assurance
Authors:
E. M. L. Vaccara, N. Brunetti, M. Calabrese, A. Garlaschi, L. Ridolfi, G. Pellecchia, M. Dordolo, C. Gavotti, F. Levrero
DOI:
10.26044/esi2021/ESI-13005
Purpose or learning objective
In our hospital, a new Hologic Selenia 3Dimensions tomosynthesis allows to perform Contrast Enhancement Digital Mammography (CEDM), that has a bigger cancer detection-rate respect to conventional Full Field Digital Mammography (FFDM), but it has the disadvantage of introducing an increased radiation exposure.
The new European Directive, transposed by Legislative Decree 101/2020, provides that the information relating to the exposure is part of the report of the medical-radiological procedure. Since the estimation of the accuracy of the effective dose (E) value given to the patient is the responsibility of the medical physics specialist and, since the effective dose is the product of the accumulated Average Glandular Dose (AGD) by the multiplication factor 0.12, it is sufficient to calculate the accuracy of the AGD to have E accuracy.
Both for FFDM and CEDM, we estimate the average discrepancy of AGD calculated respecting to that recorded on the software for a breast phantom.
Our aims are:
- To evaluate image quality
- To compare the values of CEDM AGD with FFDM AGD in a breast phantom
- To assess the accuracy of the manufacturer's AGD
- To verify compliance with the EUREF Dose limits
- And finally, to collect clinical dose data.